Browse > Article
http://dx.doi.org/10.22722/KJPM.2018.26.1.51

Discontinuation Rate of Doxepin in Insomnia Patients  

Lee, Ji Hyeon (Department of Psychiatry, College of Medicine, Catholic University of Korea)
Kim, Sung-Min (Department of Psychiatry, College of Medicine, Catholic University of Korea)
Hong, Seung-Chul (Department of Psychiatry, College of Medicine, Catholic University of Korea)
Seo, Ho-Jun (Department of Psychiatry, College of Medicine, Catholic University of Korea)
Kim, Tae-Won (Department of Psychiatry, College of Medicine, Catholic University of Korea)
Um, Yoo-Hyun (Department of Psychiatry, College of Medicine, Catholic University of Korea)
Jeong, Jong-Hyun (Department of Psychiatry, College of Medicine, Catholic University of Korea)
Publication Information
Korean Journal of Psychosomatic Medicine / v.26, no.1, 2018 , pp. 51-58 More about this Journal
Abstract
Objectives : We aimed to investigate the discontinuation rate and reasons of doxepin base prescription pattern in insomnia outpatients of psychiatry department of a university hospital. Methods : 534 patients prescribed doxepin were screened. 201 patients were included and reviewed for their medical records retrospectively. The discontinuation rate and reasons of doxepin after 2 months of prescription were investigated. Patients were divided into three groups according to the prescription patterns. The initial group, prescribed doxepin as the first hypnotic, the add-on group, prescribed doxepin while maintaining existing hypnotics, and the switching group, prescribed doxepin after discontinuation of existing hypnotics. Results : The discontinuation rate after 2 months of prescription of doxepin was 56.2%. There were significant differences in the discontinuation rate among three groups. The initial group had the highest while the add-on group had the lowest (p=0.018). In reasons for discontinuation of doxepin among three groups, lack of efficacy (p<0.001) and adverse events (p<0.001) were significantly higher in the add-on group. In the initial group, patient's refusal (p=0.022) and unknown or loss to follow up (p<0.001) were significantly higher. Conclusions : The results of this study suggested that add-on is superior than switching method and gradual reduction of existing hypnotics is necessary to maintain doxepin treatment and prevent adverse events. Additional large scale prospective studies are needed to evaluate various factors and risks of discontinuation of doxepin.
Keywords
Discontinuation; Doxepin; Insomnia;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ellis JG, Perlis ML, Neale LF, Espie CA, Bastien CH. The natural history of insomnia: focus on prevalence and incidence of acute insomnia. J Psychiatr Res 2012;46:1278-1285.   DOI
2 Leger D, Morin CM, Uchiyama M, Hakimi Z, Cure S, Walsh JK. Chronic insomnia, quality-of-life, and utility scores: Comparison with good sleepers in a cross-sectional international survey. Sleep Medicine 2012;13:43-51.   DOI
3 Soldatos CR. Insomnia in relation to depression and anxiety: Epidemiologic considerations. Journal of Psychosomatic Research 1994;38:3-8.
4 Yin J, Jin X, Shan Z, Li S, Huang H, Li P, Peng X, Peng Z, Yu K, Bao W, Yang W, Chen X, Liu L. Relationship of Sleep Duration With All-Cause Mortality and Cardiovascular Events: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies. J Am Heart Assoc 2017;6.
5 Edinger JD, Sampson WS. A primary care "friendly" cognitive behavioral insomnia therapy. Sleep 2003;26:177-182.   DOI
6 Mitchell MD, Gehrman P, Perlis M, Umscheid CA. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. BMC Family Practice 2012;13:40.   DOI
7 Rudolph U, Crestani F, Benke D, Brunig I, Benson JA, Fritschy JM, Martin JR, Bluethmann H, Mohler H. Benzo-diazepine actions mediated by specifc gamma-aminobutyric acid (A) receptor subtypes. Nature 1999;401:796-800.   DOI
8 de Haas SL, Schoemaker RC, van Gerven JM, Hoever P, Cohen AF, Dingemanse J. Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects. J Psychopharmacol 2010; 24:1619-1629.   DOI
9 Wilt TJ, MacDonald R, Brasure M, Olson CM, Carlyle M, Fuchs E, Khawaja IS, Diem S, Koffel E, Ouellette J, Butler M, Kane RL. Pharmacologic treatment of insomnia disorder: An evidence report for a clinical practice guideline by the american college of physicians. Annals of Internal Medicine 2016; 165:103-112.   DOI
10 Wilson SJ, Nutt DJ, Alford C, Argyropoulos SV, Baldwin DS, Bateson AN, Britton TC, Crowe C, Dijk DJ, Espie CA, Gringras P, Hajak G, Idzikowski C, Krystal AD, Nash JR, Selsick H, Sharpley AL, Wade AG. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 2010;24:1577-1601.   DOI
11 Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD, Clinical Guidelines Committee of the American College of P. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med 2016;165:125-133.   DOI
12 Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med 2017;13:307-349.   DOI
13 Morgenthaler T, Kramer M, Alessi C, Friedman L, Boe- hlecke B, Brown T, Coleman J, Kapur V, Lee-Chiong T, Owens J, Pancer J, Swick T. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An american academy of sleep medicine report. Sleep 2006; 29:1415-1419.   DOI
14 Holshoe JM. Antidepressants and sleep: a review. Perspect Psychiatr Care 2009;45:191-197.   DOI
15 Tassniyom K, Paholpak S, Tassniyom S, Kiewyoo J. Quetiapine for primary insomnia: a double blind, randomized controlled trial. J Med Assoc Thai 2010;93:729-734.
16 Thompson W, Quay TAW, Rojas-Fernandez C, Farrell B, Bjerre LM. Atypical antipsychotics for insomnia: a systematic review. Sleep Med 2016;22:13-17.   DOI
17 Wichniak A, Wierzbicka A. [The effects of antidepressants on sleep in depressed patients with particular reference to trazodone in comparison to agomelatine, amitriptyline, doxepin, mianserine and mirtazapine]. Pol Merkur Lekarski 2011;31: 65-70.
18 Krystal AD, Lankford A, Durrence HH, Ludington E, Jochelson P, Rogowski R, Roth T. Effcacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep 2011;34:1433-1442.
19 Wang YQ, Takata Y, Li R, Zhang Z, Zhang MQ, Urade Y, Qu WM, Huang ZL. Doxepin and diphenhydramine increased non-rapid eye movement sleep through blockade of histamine H1 receptors. Pharmacol Biochem Behav 2015;129: 56-64.   DOI
20 Krystal AD, Durrence HH, Scharf M, Jochelson P, Rogows- ki R, Ludington E, Roth T. Effcacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia. Sleep 2010;33:1553-1561.   DOI
21 Lankford A, Rogowski R, Essink B, Ludington E, Heith Durrence H, Roth T. Effcacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia. Sleep Med 2012;13:133-138.   DOI
22 Blackwell B. Drug therapy: patient compliance. The New England Journal of Medicine 1973;289:249-252.   DOI
23 Chen A. Noncompliance in community psychiatry: a review of clinical interventions. Hospital & Community Psychiatry 1991;42:282-287.
24 You JH, Woo YS, Hahn C, Choi JW, Ko HJ. Predicting factors associated with drug compliance in psychiatric out-patients of a university hospital. Korean J Psychopharmacol 2010;21:29-34.
25 Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG, Espie CA, Garcia-Borreguero D, Gjerstad M, Goncalves M, Hertenstein E, Jansson-Frojmark M, Jennum PJ, Leger D, Nissen C, Parrino L, Paunio T, Pevernagie D, Verbraecken J, Weess HG, Wichniak A, Zavalko I, Arnardottir ES, Deleanu OC, Strazisar B, Zoetmulder M, Spiegelhalder K. European guideline for the diagnosis and treatment of insomnia. J Sleep Res 2017;26:675-700.   DOI
26 Kwon JS, Shin SW, Cheong YM, Park KH. Medication compliance in psychiatric outpatients of a university hospital. Journal of Korean Neuropsychiatric Association 1997;36:523- 529.
27 Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open 2014;4:e006544.   DOI
28 Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient Barriers to and Enablers of Deprescribing: a Systematic Review. Drugs & Aging 2013;30:793-807.   DOI
29 Pollmann AS, Murphy AL, Bergman JC, Gardner DM. Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review. BMC Pharmacol Toxicol 2015;16:19.   DOI
30 Drake CL, Durrence H, Cheng P, Roth T, Pillai V, Peterson EL, Singh M, Tran KM. Arousability and Fall Risk During Forced Awakenings From Nocturnal Sleep Among Healthy Males Following Administration of Zolpidem 10 mg and Doxepin 6 mg: A Randomized, Placebo-Controlled, Four- Way Crossover Trial. Sleep 2017;40.
31 Yeung WF, Chung KF, Yung KP, Ng TH. Doxepin for insomnia: a systematic review of randomized placebo-controlled trials. Sleep Med Rev 2015;19:75-83.   DOI
32 Roth T, Heith Durrence H, Jochelson P, Peterson G, Ludington E, Rogowski R, Scharf M, Lankford A. Effcacy and safety of doxepin 6 mg in a model of transient insomnia. Sleep Med 2010;11:843-847.   DOI